Artificial intelligence to improve cytology performance in urothelial carcinoma diagnosis: results from validation phase of the French, multicenter, prospective VISIOCYT1 trial.
Fiche publication
Date publication
juillet 2023
Journal
World journal of urology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr KLEINCLAUSS François
Tous les auteurs :
Lebret T, Paoletti X, Pignot G, Roumiguié M, Colombel M, Savareux L, Verhoest G, Guy L, Rigaud J, De Vergie S, Poinas G, Droupy S, Kleinclauss F, Courtade-Saïdi M, Piaton E, Radulescu C, Rioux-Leclercq N, Kandel-Aznar C, Renaudin K, Cochand-Priollet B, Allory Y, Nivet S, Rouprêt M
Lien Pubmed
Résumé
Cytology and cystoscopy, the current gold standard for diagnosing urothelial carcinomas, have limits: cytology has high interobserver variability with moderate or not optimal sensitivity (particularly for low-grade tumors); while cystoscopy is expensive, invasive, and operator dependent. The VISIOCYT1 study assessed the benefit of VisioCyt for diagnosing urothelial carcinoma.
Mots clés
Artificial intelligence, Bladder, Cancer, Deep learning, Markers, Urothelial
Référence
World J Urol. 2023 07 22;: